(Q43221783)

English

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

scientific article published on 10 December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 November 2017

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy (English)

1 reference

Europe PubMed Central

16 November 2017

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Deborah L. White

2

1 reference

Europe PubMed Central

16 November 2017

6

object named as

T P Hughes

1 reference

Europe PubMed Central

16 November 2017

author name string

D K Hiwase

1

1 reference

Europe PubMed Central

16 November 2017

S Zrim

3

1 reference

Europe PubMed Central

16 November 2017

V Saunders

4

1 reference

Europe PubMed Central

16 November 2017

J V Melo

5

1 reference

Europe PubMed Central

16 November 2017

publication date

10 December 2009

1 reference

Europe PubMed Central

16 November 2017

1 reference

Europe PubMed Central

16 November 2017

24

1 reference

Europe PubMed Central

16 November 2017

658-660

1 reference

Europe PubMed Central

16 November 2017

3

1 reference

Europe PubMed Central

16 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2009.242

0 references

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.242

21 January 2018

Identifiers

10.1038/LEU.2009.242

1 reference

Europe PubMed Central

16 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

16 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43221783&oldid=1984138908"